Ovarian tumor cell sensitivity then resistance - to chemotherapy linked to genetic abnormality

BOSTONResearchers at Dana-Farber Cancer Institute and a team of international collaborators have identified a genetic abnormality that makes some ovarian tumor cells initially sensitive to a common chemotherapy agent, cisplatin, and then resistant to the drug over time.

Published in the May issue of Nature Medicine, the study challenges conventional thinking about how cancer cells are able to "outsmart" therapies that at first are effective against them.

"It has been thought that as normal cells evolve into cancerous ones, they acquire more and more genetic damage to the point where they gain the ability to withstand drugs that once killed them," says the study's senior author, Alan D'Andrea, MD, of Dana-Farber and Children's Hospital Boston. "While that may indeed take place, our study points to another possibility: that cancer cells can, in effect, 'go backward,' switching some genes to a normal state so they essentially disguise themselves from common therapeutic agents."

The finding represents both a hurdle to the development of new anti-cancer drugs and, paradoxically, a crucial step toward the discovery of such drugs. Scientists working on drug development now know that they are chasing more of a moving target than they may have realized. They also have a better sense, however, of how to counter these cellular shifts.

The new study stems from D'Andrea's research in Fanconi anemia, an inherited condition that places children at risk for bone marrow failure early in life and various forms of cancer as they get older. The disease is caused by a defect, or mutation, in any of seven genes that act as a tag-team to repair damaged DNA. Over the last few years, D'Andrea and his colleagues found that this gene "pathway" leads directly to BRCA1 and BRCA2, two of the best known cancer genes in human cells. When either of the BRCA genes or any of those in the Fanconi pathway are mutated, the result can be breast cancer, ovarian cancer

Contact: Bill Schaller
Dana-Farber Cancer Institute

Page: 1 2 3

Related biology news :

1. Ovarian cancer sheds tumor suppression with loss of estrogen receptor
2. Ovarian cancer detected in blood samples
3. Ovarian stimulation in mice adversely affects embryo development and implantation
4. Study Suggests Vaccine Increases Survival In Ovarian And Breast Cancer Patients Following High-Dose Chemotherapy And Autologous Stem Cell Transplant
5. UI Researchers Find Possible Genetic Link Between The X Chromosome And Ovarian Cancer
6. Gene Knockout Prolongs Ovarian Lifespan In Mice
7. Gene Once Thought To Program Ovarian Development Instead Found To Be Critical For Production Of Sperm
8. Cold Virus With P53 Gene Tested To Combat Ovarian Cancer
9. Multi-Center Study Provides Guidelines For Genetic Testing In Women With Breast Cancer: BRCA Abnormalities Multiply Risk Of Ovarian Cancer
10. Researchers identify protein promoting vascular tumor growth
11. Gene expression in liver tumors and patient prognosis

Post Your Comments:

(Date:3/5/2019)... ... March 05, 2019 , ... Join this live ... metadata-driven approach will help data analysts and bioinformaticians focus on data analysis without worrying ... that can come from different source systems. Some sources of data include:, ...
(Date:2/27/2019)... ... February 27, 2019 , ... Fluxion Biosciences, a leading developer of precision solutions ... Cancer Institute grant for further development of its ERASE-Seq liquid biopsy technology. The Phase ... lab of Dr. Omar Mian at the Cleveland Clinic. , Liquid biopsies offer the ...
(Date:2/22/2019)... ... February 20, 2019 , ... ... plans today to expand the company’s footprint in Frederick, MD after a year ... used RoosterBio’s adult human mesenchymal stem/stromal cell (hMSCs) products to streamline their product ...
Breaking Biology News(10 mins):
(Date:3/9/2019)... DIEGO (PRWEB) , ... March 07, 2019 , ... ... Technologies, is a pioneer in the development and commercialization of high performance, cutting-edge ... PhysioStim, a leading European CRO with GLP-certified expertise in cardiovascular pharmacology and electrophysiology, ...
(Date:3/5/2019)... Texas (PRWEB) , ... March 05, 2019 , ... ... a biopharmaceutical cold chain engineering firm with regulatory filing authorities, logistics network experts, ... corporate information to initiate its participation in the Inc. Verified Profile program, Inc. ...
(Date:2/27/2019)... ... February 26, 2019 , ... Superior Controls, Inc., a leading ... 140 employees on both the east and west coasts, today announced that employee ... New Hampshire. Sandmaier, a senior project engineer, joins Taggart McCormick, P.E., Anthony Whitesell, ...
(Date:2/22/2019)... ... February 20, 2019 , ... Superior Controls, Inc. ... solutions with 140 employees on both the east and west coasts, today announced the ... working out of the company’s Seabrook, New Hampshire office. In his new role, ...
Breaking Biology Technology:
Cached News: